Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Antimicrob Agents Chemother
    November 2026
  1. COSTA ACC, Lin Y-W, Chandasana H, Collins J, et al
    Population pharmacokinetic analysis of lamivudine (3TC) in HIV-exposed neonates and pediatric participants living with HIV-1 from the IMPAACT 2019 and PETITE studies.
    Antimicrob Agents Chemother. 2026 Nov 10:e0070126. doi: 10.1128/aac.00701.
    >> Share

  2. KANG W-H, Lin Y-W, Chandasana H, Collins J, et al
    Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studies.
    Antimicrob Agents Chemother. 2026 Nov 3:e0070226. doi: 10.1128/aac.00702.
    >> Share

  3. CHEN J, Wang X, Karmoker J, Johnston M, et al
    Identification of natural products for blocking Kaposi's sarcoma-associated herpesvirus entry and primary infection.
    Antimicrob Agents Chemother. 2026 Nov 2:e0115126. doi: 10.1128/aac.01151.
    >> Share

    October 2026
  4. ROBINSON M, Gillespie G, Kandala B, Ankrom W, et al
    An open-label, Phase 1 study to evaluate the drug-drug interaction between ulonivirine and the combined oral contraceptive levonorgestrel/ethinyl estradiol in female participants without HIV with a validated liquid chromatograph.
    Antimicrob Agents Chemother. 2026 Oct 28:e0022726. doi: 10.1128/aac.00227.
    >> Share

  5. NUSSBAUM JC, Pham MM, Vargo R, Liu Y, et al
    Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV.
    Antimicrob Agents Chemother. 2026 Oct 8:e0067626. doi: 10.1128/aac.00676.
    >> Share

    September 2026
  6. GUO Y, Li Y, Zhao P, Bi J, et al
    Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial.
    Antimicrob Agents Chemother. 2026 Sep 4:e0098426. doi: 10.1128/aac.00984.
    >> Share

    August 2026
  7. ROSSOUW J, Wallis R, Kornfeld H, Singhal A, et al
    The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis.
    Antimicrob Agents Chemother. 2026 Aug 6:e0074826. doi: 10.1128/aac.00748.
    >> Share

  8. WANG P, Meng Z, Zhou J, Wu H, et al
    Sorafenib enforces HIV-1 latency by selectively inhibiting PKC-driven STAT1/3 serine 727 phosphorylation.
    Antimicrob Agents Chemother. 2026 Aug 3:e0054026. doi: 10.1128/aac.00540.
    >> Share

    July 2026
  9. VAN DYK J, Waitt C, Mugerwa H, Wiesner L, et al
    Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV.
    Antimicrob Agents Chemother. 2026 Jul 17:e0059226. doi: 10.1128/aac.00592.
    >> Share

    June 2026
  10. TRAN ND, Nguyen NTQ, Vu TTT, Diep P-H, et al
    Development and validation of a rabbit model of Pseudomonas aeruginosa hyperdynamic septic shock for preclinical drug development.
    Antimicrob Agents Chemother. 2026 Jun 15:e0193625. doi: 10.1128/aac.01936.
    >> Share

  11. STOGER L, Mischlinger J, Nhampossa T, Mombo-Ngoma G, et al
    Effects of malaria intermittent preventive treatment with dihydroartemisinin-piperaquine on antiretroviral drug concentrations in African pregnant women living with HIV.
    Antimicrob Agents Chemother. 2026 Jun 12:e0033726. doi: 10.1128/aac.00337.
    >> Share

  12. CHARPENTIER C, Montrouge T, Wirden M, Avettand-Fenoel V, et al
    A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval.
    Antimicrob Agents Chemother. 2026 Jun 10:e0022826. doi: 10.1128/aac.00228.
    >> Share

  13. CHEN Q, Luo Y, Zheng Q, Tan M, et al
    Efficacy and safety of doravirine/lamivudine/tenofovir as initial treatment for people living with HIV in China.
    Antimicrob Agents Chemother. 2026 Jun 4:e0007426. doi: 10.1128/aac.00074.
    >> Share

    May 2026
  14. MISHRA T, Edwards A, Wu L
    Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4(+) T cells.
    Antimicrob Agents Chemother. 2026 May 29:e0040026. doi: 10.1128/aac.00400.
    >> Share

    April 2026
  15. XU Y, Chen L, Liu J, Wang Q, et al
    Fluconazole-induced liver injury in patients with pulmonary cryptococcosis: a comprehensive study integrating clinical cohort analysis, network toxicology, molecular docking, and transcriptomics.
    Antimicrob Agents Chemother. 2026 Apr 20:e0197625. doi: 10.1128/aac.01976.
    >> Share

  16. MOSCHESE D, Fusetti C, Lazzarin S, Giacomelli A, et al
    Seminal plasma concentrations of long-acting cabotegravir in men receiving HIV pre-exposure prophylaxis.
    Antimicrob Agents Chemother. 2026 Apr 15:e0016526. doi: 10.1128/aac.00165.
    >> Share

  17. GERLOVINA I, Berube S, Briggs J, Murie K, et al
    Classification of outcomes in antimalarial therapeutic efficacy studies with Aster.
    Antimicrob Agents Chemother. 2026 Apr 13:e0141125. doi: 10.1128/aac.01411.
    >> Share

    March 2026
  18. NEVERETTE NC, Winfield J, Chaparro-Caceres N, Ho KS, et al
    Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and prevention.
    Antimicrob Agents Chemother. 2026 Mar 23:e0140125. doi: 10.1128/aac.01401.
    >> Share

  19. YAO L, Tian T, Zou D, Lu X, et al
    Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 2026 Mar 11:e0170625. doi: 10.1128/aac.01706.
    >> Share

  20. MARANCHICK NF, Martyn-Dickens C, Enimil A, Yang H, et al
    Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV.
    Antimicrob Agents Chemother. 2026 Mar 2:e0090925. doi: 10.1128/aac.00909.
    >> Share

    February 2026
  21. ZOU S, Zhao X, Zhang Q, Xiao Y, et al
    Effectiveness and safety of ainuovirine plus lamivudine and tenofovir DF in virologically suppressed people living with HIV-1: the 48-week results of a multicenter, real-world study.
    Antimicrob Agents Chemother. 2026 Feb 3:e0110825. doi: 10.1128/aac.01108.
    >> Share

    November 2025
  22. ARORA P, Hindman JT, West S, Ling J, et al
    The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study.
    Antimicrob Agents Chemother. 2025 Nov 28:e0078125. doi: 10.1128/aac.00781.
    >> Share

    October 2025
  23. SWANSTROM AE, Oswald K, Fast R, Shoemaker R, et al
    The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection.
    Antimicrob Agents Chemother. 2025 Oct 7:e0107325. doi: 10.1128/aac.01073.
    >> Share

    September 2025
  24. TSIRIZANI L, Waalewijn H, Szubert A, Mulenga V, et al
    Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV.
    Antimicrob Agents Chemother. 2025 Sep 26:e0077125. doi: 10.1128/aac.00771.
    >> Share

  25. WANG C, Huang H, Valera L, Parcella K, et al
    Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499.
    Antimicrob Agents Chemother. 2025 Sep 3:e0030925. doi: 10.1128/aac.00309.
    >> Share

    August 2025
  26. LAI Y-T, Dingens AS, DeMouth M, Helmold Hait S, et al
    Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile.
    Antimicrob Agents Chemother. 2025 Aug 27:e0191024. doi: 10.1128/aac.01910.
    >> Share

    July 2025
  27. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
    Antimicrob Agents Chemother. 2025 Jul 31:e0005225. doi: 10.1128/aac.00052.
    >> Share

  28. LEONE PA, Losos J, Wannamaker P, D'Agostino R, et al
    VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results.
    Antimicrob Agents Chemother. 2025 Jul 23:e0025825. doi: 10.1128/aac.00258.
    >> Share

  29. RAINES SLM, Falcinelli SD, Peterson JJ, Van Gulck E, et al
    Correction for Raines et al., "Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets".
    Antimicrob Agents Chemother. 2025 Jul 21:e0081725. doi: 10.1128/aac.00817.
    >> Share

  30. CALDERIN JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, et al
    Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.
    Antimicrob Agents Chemother. 2025 Jul 1:e0009925. doi: 10.1128/aac.00099.
    >> Share

    June 2025
  31. FERNANDEZ-GONZALEZ M, Telenti G, Ledesma C, Losada-Echeberria M, et al
    Influence of patient characteristics and oral lead-in on long-acting cabotegravir and rilpivirine pharmacokinetics and outcomes in people with HIV: a real-world study.
    Antimicrob Agents Chemother. 2025 Jun 5:e0014525. doi: 10.1128/aac.00145.
    >> Share

    April 2025
  32. MARGOLIS D, Watkins M, Zhu Y
    Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants.
    Antimicrob Agents Chemother. 2025 Apr 22:e0020025. doi: 10.1128/aac.00200.
    >> Share

  33. SAWE S, Tsirizani L, Court R, Gausi K, et al
    The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
    >> Share

    March 2025
  34. MATTHEWS RP, Patel M, Liu W, Liu Y, et al
    Pharmacokinetics of islatravir in participants with moderate hepatic impairment.
    Antimicrob Agents Chemother. 2025 Mar 5:e0155324. doi: 10.1128/aac.01553.
    >> Share

    February 2025
  35. LAZZARO A, Recchia GE, Alessi F, Santinelli L, et al
    Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort.
    Antimicrob Agents Chemother. 2025 Feb 18:e0081524. doi: 10.1128/aac.00815.
    >> Share

    January 2025
  36. FILLGROVE KL, Matthews RP, Lu B, Liang Y, et al
    Nonclinical and clinical characterization of the absorption, metabolism, and excretion of islatravir.
    Antimicrob Agents Chemother. 2025 Jan 14:e0103024. doi: 10.1128/aac.01030.
    >> Share

    December 2024
  37. NDZAMBA B, Denti P, McIlleron H, Smith P, et al
    Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
    >> Share

    October 2024
  38. HAN K, D'Amico RD, Spreen WR, Ford SL, et al
    Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV.
    Antimicrob Agents Chemother. 2024 Oct 23:e0088024. doi: 10.1128/aac.00880.
    >> Share

    September 2024
  39. MARZINKE MA, Han K, Hanscom B, Guo X, et al
    Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
    Antimicrob Agents Chemother. 2024 Sep 23:e0099424. doi: 10.1128/aac.00994.
    >> Share

  40. SHIN Y, Park CM, Kim D-E, Kim S, et al
    Discovery of new acetamide derivatives of 5-indole-1,3,4-oxadiazol-2-thiol as inhibitors of HIV-1 Tat-mediated viral transcription.
    Antimicrob Agents Chemother. 2024 Sep 4:e0064324. doi: 10.1128/aac.00643.
    >> Share

  41. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
    Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
    >> Share

    August 2024
  42. ZANG X, Ankrom W, Kraft WK, Vargo R, et al
    Intracellular islatravir-triphosphate half-life supports extended dosing intervals.
    Antimicrob Agents Chemother. 2024 Aug 6:e0045824. doi: 10.1128/aac.00458.
    >> Share

    July 2024
  43. BAE J, Tantawy M, Gong Y, Langaee T, et al
    Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
    Antimicrob Agents Chemother. 2024 Jul 30:e0054924. doi: 10.1128/aac.00549.
    >> Share

  44. SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al
    Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354.
    >> Share

  45. GIGANTE V, Alm RA, Melchiorri D, Rocke T, et al
    Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
    Antimicrob Agents Chemother. 2024 Jul 15:e0053524. doi: 10.1128/aac.00535.
    >> Share

  46. VAN GULCK E, Pardons M, Nijs E, Verheyen N, et al
    Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity".
    Antimicrob Agents Chemother. 2024 Jul 2:e0081924. doi: 10.1128/aac.00819.
    >> Share

  47. MATTHEWS RP, Liu Y, Matthews C, Butterfield KL, et al
    Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults.
    Antimicrob Agents Chemother. 2024 Jul 2:e0046424. doi: 10.1128/aac.00464.
    >> Share

    June 2024
  48. DIAMOND TL, Goh SL, Ngo W, Rodriguez S, et al
    No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.
    Antimicrob Agents Chemother. 2024 Jun 12:e0033424. doi: 10.1128/aac.00334.
    >> Share

  49. MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
    How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
    >> Share

  50. RAINES SLM, Falcinelli SD, Peterson JJ, Van Gulck E, et al
    Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets.
    Antimicrob Agents Chemother. 2024 Jun 3:e0020124. doi: 10.1128/aac.00201.
    >> Share

    May 2024
  51. PANJASAWATWONG N, Avihingsanon A, Menetrey C, Ribeiro I, et al
    Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment.
    Antimicrob Agents Chemother. 2024 May 20:e0000824. doi: 10.1128/aac.00008.
    >> Share

  52. BECKEN B, Dousa KM, Johnson JL, Holland SM, et al
    Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child.
    Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319.
    >> Share

  53. HAN K, Patel P, McCallister S, Rinehart AR, et al
    Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
    Antimicrob Agents Chemother. 2024 May 6:e0147523. doi: 10.1128/aac.01475.
    >> Share

    April 2024
  54. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    >> Share

  55. CHANDASANA H, Singh R, Adkison K, Ait-Khaled M, et al
    Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Antimicrob Agents Chemother. 2024 Apr 8:e0150423. doi: 10.1128/aac.01504.
    >> Share

    March 2024
  56. COSSU MV, D'Avolio A, Gervasoni C, Giacomelli A, et al
    Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Antimicrob Agents Chemother. 2024 Mar 27:e0017524. doi: 10.1128/aac.00175.
    >> Share

  57. HAN K
    Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Antimicrob Agents Chemother. 2024 Mar 27:e0020424. doi: 10.1128/aac.00204.
    >> Share

  58. WANG C, Yu X, Ke Y, Fu Y, et al
    Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
    Antimicrob Agents Chemother. 2024 Mar 14:e0166823. doi: 10.1128/aac.01668.
    >> Share

  59. JOGIRAJU V, Weber E, Hindman J, West S, et al
    Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
    Antimicrob Agents Chemother. 2024 Mar 8:e0134423. doi: 10.1128/aac.01344.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016